去纤维钠哪里生产？

(Defitelio) is a multi-component biochemical drug developed by the Italian company Gentium SpA. It is also a mixture of single-stranded deoxyoligonucleotide sodium salts with a molecular weight of 15-30 ku, which is obtained from pig intestinal mucosal genomic DNA through controlled depolymerization. It is clinically used to treat multiple myeloma and hepatic veno-occlusive disease caused by chemotherapy and stem cell transplantation.

Defibrotide sodium (defibrotide) was first approved for marketing by the EU EMA on October 18, 2013, and received orphan drug designation. On March 30, 2016, the drug was officially approved by the US FDA. The launch of this drug has provided strong and effective help in the treatment of patients with many indications. However, unfortunately, China is not included in the countries where it has been launched. Therefore, patients currently have no choice but to purchase the drug overseas for use.

It is understood that a box of 200mg defibrinated sodium sells for around $21,600. Domestic patients who need Defitelio can purchase it from the following channels: one is purchasing on behalf of others, the other is purchasing locally, and the third is contacting domestic overseas medical service institutions (such as Medical Companion Travel) to obtain drug purchase channels. Since the first two purchase methods often face problems such as the inability to distinguish the authenticity of drugs, high round-trip costs, and complicated procedures, patients often choose the last method. Through this method, patients can effectively avoid the above problems, and at the same time, they can more conveniently obtain the safe and good medicine they need.

After purchasing defibrinated sodium, patients must follow the instructions or follow the doctor's advice: the recommended dosage is 6.25 mg/kg, given every 6 hours as a 2-hour intravenous infusion. The minimum treatment time is 21 days. If the signs and symptoms of patients with hepatic veno-occlusive disease do not resolve after 21 days, the patient should continue treatment until the symptoms are resolved.

Recommended hot articles: /newsDetail/78702.html